[Secondary prevention following myocardial infarct. Platelet aggregation inhibitors, beta receptor blockers, antiarrhythmics].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000526:Alprenolol / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000517:prevention & control*; D010644:Phenprocoumon / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects; D011217:Practolol / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D012008:Recurrence; D012737:Sex Factors; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D005343:Fibrinolytic Agents; D004176:Dipyridamole; D000526:Alprenolol; D011433:Propranolol; D010644:Phenprocoumon; D001241:Aspirin; D011217:Practolol; D013442:Sulfinpyrazone
Sekundäre Prävention nach Myokardinfarkt. Thrombozytenaggregationshemmer, beta-Rezeptorenblocker, antiarrhythmika.